- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
ImmunoPrecise Antibodies Gets DTC Eligibility For Common Shares
ImmunoPrecise Antibodies announced its common shares have been made eligible for book-entry delivery and depository services of The Depository Trust Company to facilitate electronic settlement of transfers of its common shares in the US.
ImmunoPrecise Antibodies (TSXV:IPA; OTCPINK:IPATF) announced its common shares have been made eligible for book-entry delivery and depository services of The Depository Trust Company to facilitate electronic settlement of transfers of its common shares in the US.
As quoted in the press release:
“We are pleased to have obtained DTC eligibility,” said Tom D’Orazio, CEO of ImmunoPrecise. “DTC eligibility simplifies the process of trading and transferring ImmunoPrecise shares between brokerages in the United States and reduces the costs incurred in trading shares. With our shares now DTC eligible, we expect this to lead to greater liquidity and execution speeds, as well as our shares being accessible to an even broader range of investors.”
In addition to the US OTC Market, shares of ImmunoPrecise also continue to trade on the TSX Venture Exchange.
Click here to read the full press release.
Source: www.newswire.ca
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.